Reuters reported:

Pfizer Inc (PFE.N) on Wednesday raised its full-year sales forecast for the COVID-19 vaccine it developed with Germany’s BioNTech by 29% to $33.5 billion, as nations stock up on doses for the rest of the year.

The company also said it could apply for an emergency use authorization for a potential booster dose as early as August, reiterating that a third shot will likely be needed to enhance protection amid a resurgence in infections in many countries.

Similar Posts

Leave a Reply

Your email address will not be published.